New eczema drug shows promise in Mid-Stage trial
Symptom relief
Recruiting now
This study tests an experimental drug called BFB759 for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with standard creams. About 225 participants will receive either BFB759 or a placebo for up to 40 weeks. Researchers will track changes in skin r…
Phase: PHASE2 • Sponsor: Bluefin Biomedicine, Inc. • Aim: Symptom relief
Last updated May 18, 2026 11:59 UTC